A Temporary Reprieve from New Tariffs In a significant, albeit potentially temporary, development for one of the nation’s most critical sectors, the US pharmaceutical industry has successfully avoided the immediate impact of new pharmaceutical tariffs under President Donald Trump’s recent broad trade measures. This initial exemption has provided a moment of relief, allowing complex global supply chains to continue functioning…